The hypothesis that MDM2 provokes anti-therapeutic resistance in human malignancies was initially validated through a study performed on epidermoid carcinoma where the MDM2-p53 regulatory loop contributed to the development of resistance against cisplatin[114]. Here, MDM2 is linked to squamous cell carcinoma.